See more : Mitre Mining Corporation Limited (MMC.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Revelation Biosciences, Inc. (REVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Revelation Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Dawushan Farm Technology Co., Ltd. (6952.TW) Income Statement Analysis – Financial Results
- Container Corporation of India Limited (CONCOR.BO) Income Statement Analysis – Financial Results
- PTC Inc. (PTC) Income Statement Analysis – Financial Results
- Entergy Corporation (ETY.DE) Income Statement Analysis – Financial Results
- Dagang NeXchange Berhad (4456.KL) Income Statement Analysis – Financial Results
Revelation Biosciences, Inc. (REVB)
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 25.05K | 40.01K | 69.17K | 0.00 | 0.00 |
| Gross Profit | -25.05K | -40.01K | -69.17K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.15M | 5.38M | 6.91M | 2.56M | 0.00 |
| General & Administrative | 4.51M | 5.49M | 5.04M | 1.23M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 144.26K | 0.00 |
| SG&A | 4.51M | 5.49M | 5.04M | 145.49K | 3.64K |
| Other Expenses | 0.00 | 34.96K | -36.35K | 0.00 | 0.00 |
| Operating Expenses | 8.66M | 10.86M | 11.95M | 145.49K | 3.64K |
| Cost & Expenses | 8.66M | 10.86M | 11.95M | 145.49K | 3.64K |
| Interest Income | 0.00 | 0.00 | 0.00 | 10.92K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 25.05K | 40.01K | 69.17K | 3.80M | 171.86K |
| EBITDA | -95.21K | -10.84M | -11.93M | -145.49K | -3.64K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.66M | -10.86M | -11.95M | -145.49K | -3.64K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.54M | 34.96K | -36.35K | -1.49M | 2.00 |
| Income Before Tax | -120.25K | -10.83M | -11.99M | -1.63M | -3.64K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -34.96K | -219.78K | -3.80K | -171.86K |
| Net Income | -120.25K | -10.79M | -11.99M | -1.63M | -3.64K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.53 | -600.77 | -1.28K | -188.18 | -0.42 |
| EPS Diluted | -0.53 | -600.77 | -1.28K | -188.18 | -0.42 |
| Weighted Avg Shares Out | 228.00K | 17.97K | 9.40K | 8.66K | 8.66K |
| Weighted Avg Shares Out (Dil) | 228.64K | 17.97K | 9.40K | 8.66K | 8.66K |
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10
How an Election Impacts Penny Stocks
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
Source: https://incomestatements.info
Category: Stock Reports